

JOSH GREEN, M.D.
GOVERNOR
KE KIA'ĀINA



RYAN YAMANE
DIRECTOR
KA LUNA HO'OKELE

JOSEPH CAMPOS II
DEPUTY DIRECTOR
KA HOPE LUNA HO'OKELE

STATE OF HAWAII
KA MOKU'ĀINA O HAWAI'I
DEPARTMENT OF HUMAN SERVICES
KA 'OIHANA MĀLAMA LAWELawe KANAKA
Med-QUEST Division
Clinical Standards Office
P.O. Box 700190
Kapolei, Hawai'i 96709-0190

TRISTA SPEER
DEPUTY DIRECTOR
KA HOPE LUNA HO'OKELE

MINUTES OF REMOTE MEETING
Med-QUEST Drug Use Review (DUR) Board

Date: May 8, 2024
Time: 12:00 pm

Remote Meeting Location: Zoom Meeting participation for members and the public:
<https://medquest-hawaii-gov.zoom.us/j/83887626293?pwd=biRmWyKswZlCcBuLLGZskQqCa5a9RO.1>

In-Person Location:
Kakuhihewa Building
Conference Rooms 577A and 577B
601 Kamokila Blvd., Kapolei, Hawaii 96707

Members Present:

Dr. James Lumeng, Chair
Wendell Au, Vice-Chair, Pharmacist
Eddie Fox, Medical Service Representative
Kathleen T. Kang-Kaulupali, Clinical Standards Office (CSO) DUR Coordinator, Pharmacist
Miki Lei Morita, Pharmacist
Reed Muraoka, Pharmacist
Dr. Curtis Toma, CSO Medical Director
Dr. Greg Yuen

Members Absent:

Staff present:

Erin Gomez, CSO, Office Assistant
Marcy Healey, Registered Nurse, Interim CSO Administrator
Julie Jay, CSO Secretary
Kathleen T. Kang-Kaulupali, CSO DUR Coordinator, Pharmacist
Dr. Curtis Toma, CSO Medical Director

MINUTES OF REMOTE MEETING
Med-QUEST Drug Use Review (DUR) Board
May 8, 2024

- I. Vice-Chair Wendel Au called the meeting to order at 12:05 pm and welcomed participants to the meeting. He proceeded with a roll call of DUR Board members. A quorum of 6 members present was reported by the DUR Coordinator. The Board members were informed to declare if they were not alone. Each participating Board members declared that they were alone. Other support members of the Drug Use Review Board were noted and declared that they were alone: Gary Peton, Conduent Government Healthcare, pharmacist (present) and Dr. Lynette Honbo, Conduent Government Healthcare, Medical Consultant (present).
- II. The February 14, 2024 meeting minutes were reviewed by the Board. (Dr. James Lumeng joined the meeting.) There was no public testimony. Without further discussion, it was moved by Eddie Fox to accept the minutes as presented and the motion was seconded by Dr. Lumeng. The motion passed approved with no opposition and no abstentions.
- III. Dental Program
 - a. Gary Peton shared highlights of the Dental Program paid claims data for the first quarter of 2024. 5,190 claims were paid at a cost less than \$150,000. One prior authorization (PA) request was received for a formulary drug; there were no denials. Controlled drugs utilization was like the last several quarters.
 - b. Kathleen Kang-Kaulupali presented calendar year 2023 controlled drugs utilization.
 - i. The lowered quantity limits were effective (from 5 down to 3-day supplies). There are no provider or patient outliers for hydrocodone and oxycodone use.
 - ii. One dental provider was selective for a post payment review, not an oral surgeon, prescribing oxycodone and found the following: Appropriate antibiotics with chlorhexidine claims, no anti-inflammatories, hydrocodone and oxycodone claims. One patient with multiple antibiotic claims was selected for sampling and further review: no polypharmacy, no dental provider shopping, but 2 months of repeat visits for same prescription combination of antibiotic and oxycodone. Prescription Drug Monitoring Program (PDMP) access for Medicaid to check provider and patient is not yet available to MQD. Patient dental services and QUEST Integrated (QI) plan medication profile reviewed. The review found benzodiazepines on QI with opioids on FFS by the dental prescriber. Direct provider education was discussed.
 - c. Fluoride coverage for children 19 years of age and less from paid claims was presented by Kathleen T. Kang-Kaulupali. (Dr. Toma joined the meeting.)

MINUTES OF REMOTE MEETING
 Med-QUEST Drug Use Review (DUR) Board
 May 8, 2024

- i. On the February 14, 2023 meeting, DUR identified fluoride prescribing of the covered outpatient drugs (COD) for children has increased after COVID and adult dental coverage implementation. More dental providers are participating Medicaid providers prescribing fluoride for children.
- ii. Additional analysis was requested and found refilled fluoride dental claims for children under age 19 years for calendar year 2023 at 29% of the 2,000 fluoride claims paid.
- iii. Other options for fluoride are varnish (D1206) and topical application (D1208) by dentists and medical providers (i.e., pediatricians during well-child examinations, CPT 99188). Fluoride varnish and topical application do not bill the fluoride on pharmacy claims. The fluoride is bundled into the billing and payment. They are viewed to evaluate access for the children to fluoride treatment not for DUR.
 - 1. Paid fluoride varnish and topical application claims for June 1 - June 7, 2023, summary estimates.

Fluoride (Non-COD)	Submitted claims for calendar year 2023	Submitted claims for June 1-7, 2023	Rates during June 1-7, 2023	Rates retroactive to January 1, 2024, implemented April 2024
Varnish D1206	85,800	1,800	\$23.59	\$24.66?
Topical application D1208	22,600	400	\$21.90	\$24.66?
Topical application CPT 99188	0	0	0	\$24.66?

2. Paid fluoride drug claims for June 1 - June 7, 2023 (<19yo) summary estimates for comparison.

Fluoride (COD)	Number of Claims	First Fill	Refill	Age Range
Drops	4	4	0	3-8yo
Chew tabs (Fl alone and in multivitamins)	23	11	12	2-10yo
Toothpaste	21	19	2	9-17yo
Total	48	34	14	
% of Total		71%	29%	

iv. Dental COD fluoride use is probably lower utilization than non-COD fluoride for children. (Age analysis is not available at this time for non-COD fluoride and medical claims of COD fluoride and multiple vitamins with fluoride for children were not accessed.) This information will be shared with Dr. Uchida, CSO dental consultant.

d. No public testimony was shared. No motion was made.

IV. State of Hawaii Organ and Tissue Transplant (SHOTT) Program was presented by Gary Peton. Expensive drug claims greater than \$1,000 for the first quarter of 2024 were reviewed for highlights finding 45 claims at a cost under \$500,000 from specialty and hospital pharmacies and no prior authorization requests.

- a. One drug, Adcetris®, for 4 claims with high “submitted” cost for reimbursement had a higher than FDA approved clinical dosing and possibly incorrect units billed. This is usually the provider’s biller error, not the provider. The claims must be reversed and re-sent with the correct units. This will result in a recovery of payment made by MQD then MQD is required to pay back the drug rebate to the labeler for the drug. Educational outreach and additional past payment review of prior years for this drug are considered.
- b. For the one Ozempic® claim Dr. Lumeng asked if a diagnosis code is required for payment. Gary Peton informed that none is required at this time.
- c. No public testimony was shared. No motion was made.

V. FFY 2023 naloxone utilization was presented by Gary Peton.

- a. Quantities reported by drug rebate as dispensed have increased from first quarter into the third quarter then decreased in the fourth quarter. Overall, this

remains low for FFS and MCOs combined together. Nasal sprays are most claims, not the injectables.

- b. Wendell Au shared that fentanyl overdoses are on the rise in Hawaii.
 - c. Kathleen Kang-Kaulupali shared that the City and County of Honolulu has Ordinance 23-24 as of January 1, 2024. This requires specific establishments with a liquor license to train managers and carry on-premises naloxone nasal spray. Information can be viewed at <https://www.honolulu.gov/cms-bfs-liq-menu/site-bfs-liq-sitearticles/54340-narcans-faq-s.html>. (No longer available in June 2024.)
 - d. No public testimony was shared. No motion was made.
- VI. The next DUR Board Meeting is Wednesday, August 14, 2024. For the November meeting Kathleen Kang-Kaulupali requested a change of date to the first or third Wednesday of the month. There was no public testimony. Without further discussion, the meeting was adjourned at 12:47 pm. The motion passed unanimously with no opposition and no abstentions.